{"id":"https://openalex.org/W4408724928","doi":"https://doi.org/10.1093/bjd/ljaf045","title":"Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged \u2265 13 years: efficacy and safety data from a phase II/III study","display_name":"Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged \u2265 13 years: efficacy and safety data from a phase II/III study","publication_year":2025,"publication_date":"2025-02-18","ids":{"openalex":"https://openalex.org/W4408724928","doi":"https://doi.org/10.1093/bjd/ljaf045","pmid":"https://pubmed.ncbi.nlm.nih.gov/40112876"},"language":"en","primary_location":{"id":"doi:10.1093/bjd/ljaf045","doi":"https://doi.org/10.1093/bjd/ljaf045","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljaf045","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1093/bjd/ljaf045","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000565136","display_name":"Hiroo Yokozeki","orcid":"https://orcid.org/0000-0002-5773-9485","observed_orcids":["https://orcid.org/0000-0002-5773-9485"]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hiroo Yokozeki","raw_affiliation_strings":["Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo ,"],"raw_orcid":"https://orcid.org/0000-0002-5773-9485","affiliations":[{"raw_affiliation_string":"Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo ,","institution_ids":["https://openalex.org/I125602781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087617455","display_name":"Hiroyuki Murota","orcid":"https://orcid.org/0000-0002-0450-1377","observed_orcids":["https://orcid.org/0000-0002-0450-1377"]},"institutions":[{"id":"https://openalex.org/I43777268","display_name":"Nagasaki University","ror":"https://ror.org/058h74p94","country_code":"JP","type":"education","lineage":["https://openalex.org/I43777268"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroyuki Murota","raw_affiliation_strings":["Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,"],"raw_orcid":"https://orcid.org/0000-0002-0450-1377","affiliations":[{"raw_affiliation_string":"Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,","institution_ids":["https://openalex.org/I43777268"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006984166","display_name":"Takayo Matsumura","orcid":"https://orcid.org/0000-0002-0986-8469","observed_orcids":["https://orcid.org/0000-0002-0986-8469"]},"institutions":[{"id":"https://openalex.org/I4210157255","display_name":"Maruho (Japan)","ror":"https://ror.org/05hj3gh79","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210157255"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takayo Matsumura","raw_affiliation_strings":["Clinical Development Department, Maruho Co., Ltd , Kyoto ,"],"raw_orcid":"https://orcid.org/0000-0002-0986-8469","affiliations":[{"raw_affiliation_string":"Clinical Development Department, Maruho Co., Ltd , Kyoto ,","institution_ids":["https://openalex.org/I4210157255"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5000565136"],"corresponding_institution_ids":["https://openalex.org/I125602781"],"apc_list":{"value":3731,"currency":"GBP","value_usd":4920},"apc_paid":{"value":3731,"currency":"GBP","value_usd":4920},"fwci":8.5667,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.97983808,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"193","issue":"1","first_page":"56","last_page":"65"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prurigo-nodularis","display_name":"prurigo nodularis","score":0.9179999828338623},{"id":"https://openalex.org/keywords/nemolizumab","display_name":"nemolizumab","score":1.0},{"id":"https://openalex.org/keywords/topical-corticosteroids","display_name":"topical corticosteroids","score":0.9860000014305115},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.7580000162124634},{"id":"https://openalex.org/keywords/pruritus","display_name":"pruritus","score":0.6840000152587891},{"id":"https://openalex.org/keywords/disease-severity","display_name":"disease severity","score":0.6840000152587891},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9760000109672546},{"id":"https://openalex.org/keywords/sleep-disturbance","display_name":"sleep disorders","score":0.5429999828338623},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8519999980926514},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.6620000004768372},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.6119999885559082},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.4429999887943268},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.4449999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9248810410499573},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7163114547729492},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.685611367225647},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.6844152212142944},{"id":"https://openalex.org/C2776266956","wikidata":"https://www.wikidata.org/wiki/Q3924802","display_name":"Prurigo nodularis","level":2,"score":0.6752572655677795},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5698937773704529},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5208940505981445},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5166709423065186},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5105355978012085},{"id":"https://openalex.org/C2776804153","wikidata":"https://www.wikidata.org/wiki/Q210420","display_name":"Corticosteroid","level":2,"score":0.489420086145401},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.44432389736175537},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43659740686416626},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34511542320251465},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.33825066685676575},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.14483079314231873},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000305","descriptor_name":"Adrenal Cortex Hormones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000305","descriptor_name":"Adrenal Cortex Hormones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011536","descriptor_name":"Prurigo","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011537","descriptor_name":"Pruritus","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011537","descriptor_name":"Pruritus","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1093/bjd/ljaf045","doi":"https://doi.org/10.1093/bjd/ljaf045","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljaf045","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},{"id":"pmid:40112876","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40112876","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The British journal of dermatology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1093/bjd/ljaf045","doi":"https://doi.org/10.1093/bjd/ljaf045","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljaf045","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"},{"id":"https://openalex.org/F8020440731","display_name":"Maruho","ror":"https://ror.org/05hj3gh79"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W182910583","https://openalex.org/W2082850379","https://openalex.org/W2096991001","https://openalex.org/W2318741017","https://openalex.org/W2528307463","https://openalex.org/W2593200577","https://openalex.org/W2910932455","https://openalex.org/W2914603675","https://openalex.org/W2969147585","https://openalex.org/W2969960972","https://openalex.org/W3008008049","https://openalex.org/W3026551947","https://openalex.org/W3040869725","https://openalex.org/W3106854925","https://openalex.org/W3129621188","https://openalex.org/W3134370107","https://openalex.org/W3158784612","https://openalex.org/W3208491758","https://openalex.org/W3216784684","https://openalex.org/W4285389891","https://openalex.org/W4385406845","https://openalex.org/W4387965403","https://openalex.org/W4390272830","https://openalex.org/W4390838081","https://openalex.org/W4391443113","https://openalex.org/W4391746574","https://openalex.org/W4392547304","https://openalex.org/W4393026533","https://openalex.org/W4394868977"],"related_works":["https://openalex.org/W4394868977","https://openalex.org/W4408324831","https://openalex.org/W6892087220","https://openalex.org/W4404755564","https://openalex.org/W4415321652","https://openalex.org/W4401435997","https://openalex.org/W7127296705","https://openalex.org/W6967305815","https://openalex.org/W7160847025","https://openalex.org/W4401436079"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,173],"biologic":[2],"therapy":[3],"nemolizumab":[4,47,90,112,127,194,211],"has":[5],"been":[6],"shown":[7],"to":[8,18,68,88,121,254,289,326],"improve":[9],"the":[10,43,70,108,123,133,147,166,178,187,231,269,291],"signs":[11],"and":[12,34,56,67,159,197,205,222,236,273,275,280,296,324,336,346],"symptoms":[13],"of":[14,28,46,53,149,161,168,181,245,271,294,308,342,351],"prurigo":[15,150],"nodularis":[16],"(PN)":[17],"a":[19,242,250,261,266],"significantly":[20],"greater":[21],"extent":[22],"than":[23],"placebo":[24],"over":[25,37,348],"16":[26,105,204,221],"weeks":[27,103,203,350],"treatment.":[29],"We":[30],"now":[31],"report":[32],"efficacy":[33,201],"safety":[35,71,356],"data":[36],"68":[38,349],"weeks.":[39,106],"OBJECTIVES:":[40],"To":[41],"evaluate":[42],"long-term":[44],"impact":[45],"on":[48],"pruritus,":[49,256,311,343],"disease":[50],"severity,":[51,265],"quality":[52],"life":[54,282],"(QoL)":[55],"topical":[57],"corticosteroid":[58],"(TCS)":[59],"usage":[60],"in":[61,65,200,230,258,263,268,278,310,329],"patients":[62,75,118,208,246,285],"with":[63,97,177,353],"PN":[64,264,312,344],"Japan,":[66],"confirm":[69],"profile.":[72],"METHODS:":[73],"Asian":[74],"aged":[76],"\u2265":[77],"13":[78],"years":[79],"were":[80,119,234,286,322],"randomly":[81],"assigned":[82],"(1":[83],":":[84,86],"1":[85],"1)":[87],"receive":[89],"30":[91,212],"mg,":[92,213],"60":[93],"mg":[94],"or":[95,125,314],"placebo,":[96],"concomitant":[98],"medium-potency":[99,295],"TCS,":[100],"every":[101],"4":[102],"for":[104],"For":[107],"subsequent":[109],"52":[110],"weeks,":[111],"treatment":[113,240,318],"was":[114,175,305],"continued,":[115],"while":[116],"placebo-treated":[117],"reallocated":[120],"either":[122],"30-mg":[124],"60-mg":[126,232],"groups.":[128],"Efficacy":[129],"outcome":[130],"measures":[131,164,341],"included":[132,165],"Peak":[134],"Pruritus":[135],"Numerical":[136],"Rating":[137],"Scale":[138],"(PP-NRS),":[139],"5-level":[140],"itch":[141],"scale,":[142],"Investigator's":[143],"Global":[144],"Assessment":[145],"(IGA),":[146],"number":[148,270],"nodules,":[151,272],"Insomnia":[152],"Severity":[153],"Index,":[154],"Dermatology":[155],"Life":[156],"Quality":[157],"Index":[158],"use":[160],"TCS.":[162],"Safety":[163],"frequency":[167],"treatment-emergent":[169],"adverse":[170],"events":[171],"(TEAEs).":[172],"trial":[174],"registered":[176],"Japan":[179],"Registry":[180],"Clinical":[182],"Trials":[183],"(jRCT2011200017).":[184],"RESULTS:":[185],"In":[186,207],"modified":[188],"intention-to-treat":[189],"population":[190],"(n":[191],"=":[192],"226),":[193],"provided":[195],"sustained":[196],"continuing":[198],"improvements":[199,248,257,277,338],"between":[202],"68.":[206],"who":[209],"received":[210],"PP-NRS":[214],"had":[215],"decreased":[216],"by":[217,223,300],"60.5%":[218],"at":[219,225,301],"week":[220,226],"78.6%":[224],"68;":[227],"respective":[228],"decreases":[229],"group":[233],"55.1%":[235],"76.5%.":[237],"Across":[238],"all":[239],"groups,":[241],"large":[243],"proportion":[244],"experienced":[247],"indicating":[249,260],"reduction":[251,262],"from":[252],"moderate-to-severe":[253],"mild":[255,323],"IGA":[259],"decrease":[267],"rapid":[274],"durable":[276,337],"sleep":[279],"daily":[281,292],"activities.":[283],"Nemolizumab-treated":[284],"also":[287],"able":[288],"reduce":[290],"quantity":[293],"higher":[297],"TCS":[298],"used":[299],"least":[302],"half.":[303],"There":[304],"no":[306,354],"indication":[307],"relapse":[309],"severity":[313,345],"QoL":[315,347],"scores":[316],"following":[317],"cessation.":[319],"Most":[320],"TEAEs":[321],"similar":[325],"those":[327],"reported":[328],"prior":[330],"studies.":[331],"CONCLUSIONS:":[332],"Nemolizumab":[333],"elicited":[334],"continuous":[335],"across":[339],"multiple":[340],"treatment,":[352],"new":[355],"concerns.":[357]},"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2025-03-22T00:00:00"}